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Decreased S-Nitrosylation of Tissue Transglutaminase
Contributes to Age-Related Increases in Vascular Stiffness
Lakshmi Santhanam,* Eric C. Tuday,* Alanah K. Webb,* Phillip Dowzicky, Jae Hyung Kim,
Young Jun Oh, Gautam Sikka, Maggie Kuo, Marc K. Halushka, Anne M. Macgregor, Jessilyn Dunn,
Sarah Gutbrod, David Yin, Artin Shoukas, Daniel Nyhan, Nicholas A. Flavahan,
Alexey M. Belkin, Dan E. Berkowitz
Rationale: Although an age-related decrease in NO bioavailability contributes to vascular stiffness, the underlying
molecular mechanisms remain incompletely understood. We hypothesize that NO constrains the activity of the
matrix crosslinking enzyme tissue transglutaminase (TG2) via S-nitrosylation in young vessels, a process that is
reversed in aging.
Objective: We sought to determine whether endothelium-dependent NO regulates TG2 activity by S-nitrosylation
and whether this contributes to age-related vascular stiffness.
Methods and Results: We first demonstrate that NO suppresses activity and increases S-nitrosylation of TG2 in
cellular models. Next, we show that nitric oxide synthase (NOS) inhibition leads to increased surface and
extracellular matrix–associated TG2. We then demonstrate that endothelium-derived bioactive NO primarily
mediates its effects through TG2, using TG2/ mice chronically treated with the NOS inhibitor L-NG-
nitroarginine methyl ester (L-NAME). We confirm that TG2 activity is modulated by endothelium-derived
bioactive NO in young rat aorta. In aging rat aorta, although TG2 expression remains unaltered, its activity
increases and S-nitrosylation decreases. Furthermore, TG2 inhibition decreases vascular stiffness in aging rats.
Finally, TG2 activity and matrix crosslinks are augmented with age in human aorta, whereas abundance remains
unchanged.
Conclusions: Decreased S-nitrosylation of TG2 and increased TG activity lead to enhanced matrix crosslinking and
contribute to vascular stiffening in aging. TG2 appears to be the member of the transglutaminase family
primarily contributing to this phenotype. Inhibition of TG2 could thus represent a therapeutic target for
age-associated vascular stiffness and isolated systolic hypertension. (Circ Res. 2010;107:117-125.)
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Aging is associated with alterations in the properties ofall elements of the vascular wall including endothe-
lium, vascular smooth muscle, and matrix.1 These changes
result in increased vascular stiffness and isolated systolic
hypertension. In addition, increased vascular stiffness
promotes atherosclerosis at various sites in the vascular
tree, such as the carotid artery.2,3 Both dynamic changes
(alterations in endothelial function and effects on vascular
smooth muscle contractility), as well as structural alter-
ations (eg, fracturing of elastin, increased collagen content,
and accumulation of advanced glycation end products)
have been described in aging. Vessel structure can addi-
tionally be regulated by alterations in matrix crosslinking.1
Transglutaminases (TGs) are enzymes that catalyze a
transamidation reaction, leading to the crosslinking of
proteins through the formation of the stable N--(-
glutamyl)lysine isopeptide bonds.4,5 At least 3 of the 9
members of the TG superfamily are expressed in vascular
systems. Tissue transglutaminase (TG2) in particular is
ubiquitously expressed in vasculature, including in endo-
thelial cells, smooth muscle cells, fibroblasts, and mono-
cytes/macrophages.4 –11 TG2 is confined mainly to the
cytosol, and a portion of it is associated with the cell
membrane and secreted out of the cell to the extracellular
matrix (ECM) through an as yet unidentified mechanism.4
The reaction catalyzed by TG2 is dependent on its loca-
tion: cytosolic TG2 acts mainly as a GTPase and extracel-
lular TG2 catalyzes the transamidation reaction.4,5 The role
of TG2 in regulating endothelial barrier function,4,12 small
Original received December 17, 2009; revision received May 10, 2010; accepted May 11, 2010.
From the Johns Hopkins University School of Medicine (L.S., E.C.T., A.K.W., P.D., J.H.K., Y.J.O., G.S., M.K., M.K.H., A.M.M., J.D., S.G., D.Y.,
A.S., D.N., N.A.F., D.E.B.), Baltimore, Md; Anesthesiology and Pain Medicine (Y.J.O.), Anesthesia and Pain Research Institute, Yonsei University
College of Medicine, Seoul, Korea; and Center for Vascular Inflammatory Diseases (A.M.B.), University of Maryland School of Medicine.
*These authors contributed equally to this work.
Correspondence to Dan E. Berkowitz, Johns Hopkins University School of Medicine, 720 Rutland Ave, Traylor 621, Baltimore MD 21205. Phone:
410-614-1517; Fax: 410-614-0019. E-mail dberkow1@jhmi.edu
© 2010 American Heart Association, Inc.
Circulation Research is available at http://circres.ahajournals.org DOI: 10.1161/CIRCRESAHA.109.215228
117
 at CONS KESLI on December 23, 2013http://circres.ahajournals.org/Downloaded from 
artery remodeling,7 induction of vascular calcification
program,10 and atherosclerosis4,13 is emerging.
Crosslinking activity of TG2 has been shown to be inhibited
in vitro by NO through protein S-nitrosylation14,15 of key
cysteine residues. Furthermore, NO reverses small artery re-
modeling by TG2 in mice.7,10 In addition to directly
modulating crosslinking activity, NO is shown to influence
TG2 subcellular distribution in fibroblasts,16 wherein the
NO donor SNAP was shown to decrease the deposition of
TG2 to the ECM over 72 hours. It is well established that
endothelial NO bioavailability diminishes with aging.17,18
We therefore tested the hypothesis that decreased NO
bioavailability contributes to an increase in TG activity in
aging vessels. In this study, we demonstrate that endothe-
lial nitric oxide synthase (NOS)-dependent NO regulates
TG2 crosslinking activity and location in endothelial cells.
Decreased endothelium-dependent NO synthesis in the
aging vasculature leads to reduced TG2 S-nitrosylation
and, thus, enhanced transamidation activity. This, in turn,
results in increased crosslinking of matrix proteins and,
consequently, to decreased compliance and increased stiff-
ness of aging conduit blood vessels.
Methods
An expanded Methods section is available in the Online Data
Supplement at http://circres.ahajournals.org.
Animals
The animal protocols used in this report have been approved by
the Johns Hopkins University School of Medicine Institutional
Animal Care and Use Committee. Fisher 344 rats were used for
this study and were supplied by the National Institute of Aging.
Young animals were 3 months of age, whereas old animals were
between 22 to 24 months of age. Male TG2/ mice (a kind gift
from Robert Graham, Victor Chang Cardiovascular Institute, New
South Wales, Australia) were used (3 to 5 months of age) in the
study with BL6129S as background. All animals were fed ad
libitum and had free access to drinking water.
Cell Cultures
Human aortic endothelial cells (HAECs) were purchased from
Cascade Biologics, cultured using ECM Media (ScienCell Labs),
and used between passages 7 and 10. Intact cells were treated as
indicated and used to determine TG2 activity, expression, and
S-nitrosylation.
Shear Stress
HAECs were sheared at 20 dyne/cm2 (400 rpm) using a cone-
and-plate viscometer as described elsewhere.19 –21
TG2 Expression
Expression was determined by Western blotting.
TG Activity Assay
A dot blot assay was used to determine TG activity as described22
with minor modifications (see the Online Data Supplement for
details). A time course of biotin(amido)pentylamine incorporation
in HAECs is shown in Online Figure I (A) and a comparison to
the standard Western blotting approach is provided (Online
Figure I, B).
S-Nitrosylation Assay
TG2 S-nitrosylation was determined using the biotin switch
assay23 in cell lysates/tissue homogenates. Because the activity
assay also relies on biotinylation, the S-nitrosylation assays were
performed on a separate set of samples in parallel with the activity
assays.
Isolation of Cell Surface Proteins and ECM
Cell surface proteins were enriched using sulfo-NHS-LC biotin
(Pierce) following the protocol of the manufacturer. ECM fraction
was recovered by removing cells and nuclear material following
the protocol of Soucy and Romer.24
Immunofluorescent Staining of TG2
HAECs were grown on fibronectin-coated coverslips and treated
as indicated. Extracellular/ECM associated TG2 was first stained
in live cells by incubating with TG2 primary followed by
Cy3-conjugated secondary antibody. Cells were then fixed, per-
meabilized, and intracellular TG2 labeled by incubating with TG2
primary followed by Cy5-conjugated secondary antibody. Sam-
ples were then mounted, sealed, and imaged on a Nikon Eclipse
80i equipped with a photometrics CoolSnap HQ2 camera (Cy3,
green; Cy5, red). The entire labeling procedure was performed in
the dark and at 4°C (see the Online Data Supplement for details).
In Vivo NOS Inhibition in Mice
Wild-type (WT) (BL6129S) and TG2/ mice were used. Ani-
mals were randomized into 2 groups and implanted with an
osmotic pump (Alzet) filled with a 4-week dose of either
L-NG-nitroarginine methyl ester (L-NAME) (20 mg/kg per day) or
vehicle control.
In Vivo Inhibition of TG in Aging Rats
Eighteen- to 19-month-old rats were randomized to 2 groups and
implanted with an osmotic pump, filled with a 4-week dose of
either cystamine (40 mg/kg per day) or vehicle control. Pumps
were exchanged every 4 weeks for 3 months.
Pulse Wave Velocity Measurement
Aortic pulse wave velocity (PWV) was measured using high-
frequency Doppler with a Doppler Signal Processing Workstation
(Indus Instruments) as previously described.25,26 Blood pressure
was measured concurrently (see the Online Data Supplement for
details).
Carotid Artery Compliance
The carotid artery was dissected and cannulated in a perfusion
chamber. The artery was perfused with oxygenated calcium-free
Krebs buffer using a peristaltic pump (Cole-Parmer Instrument
Co), which also continuously monitored perfusion pressure.
Pressure was incrementally increased from 0 to 100 mm Hg in
steps of 10 mm Hg, each for 30 second intervals. Vessel outer
diameter was simultaneously recorded using microscopic imaging
Non-standard Abbreviations and Acronyms
DTT dithiothreitol
ECM extracellular matrix
GSNO S-nitrosoglutathione
HAEC human aortic endothelial cell
L-NAME L-NG-nitroarginine methyl ester
NOS nitric oxide synthase
PWV pulse wave velocity
TG transglutaminase
TG2 tissue transglutaminase
WT wild type
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and video dimension analysis (Analog Digital Instruments).
Compliance (ability to stretch and hold volume) and distensibility
(ability to stretch; elastic property of vessel) were calculated from
these data. It is important to note that pressure was measured at
the pump proximal to the vessel, and, thus, actual vessel pressure
may be different depending on the resistances exerted by com-
ponents of the flow circuit. This, however, remains constant for
all experimental groups.
Human Tissue
Thoracic descending aortic segments for immunohistochemistry
and TG activity were taken from 16 subjects (8 young [33 to 49
years old] and 8 old [62 to 101 year old]) undergoing autopsy as
part of a wider study of vascular tissues as described.27 The
collection of all tissues was approved by the institutional review
board of The Johns Hopkins Hospital.
Data Analysis
All Western blots and dot blots were analyzed by densitometry
using the ImageJ software (NIH). Results are expressed as a
percentage change relative to the average value measured in the
baseline group. Statistics were performed using GraphPad Prism
software. One-way ANOVA with Bonferroni or Tukey correction
were used to compare 3 or more groups; unpaired t test was used
to compare 2 groups. All data are represented as meansSEM.
Results
TG2 Is Regulated by S-Nitrosylation in
Cellular Models
We first established the dependence of TG crosslinking
activity on bioactive NO in 2 cellular models: NIH3T3
cells overexpressing myc-tagged TG2 (Online Figure II)
and HAECs (Figure 1A). Intact cells were pretreated with
NO donor (S-nitrosoglutathione [GSNO]; 200 mol/L, 1
hour), reducing agent (dithiothreitol [DTT]; 200 mol/L, 1
hour), or NOS inhibitor (L-NAME; 200 mol/L, 2 hours).
Cystamine (1 mmol/L, 1 hour) was used to inhibit TG
crosslinking activity. Activity was measured in intact cells
using the biotin(amido)pentylamine (1 mmol/L, 4 hours)
incorporation assay. TG2 S-nitrosylation was measured in
cell lysates using the biotin switch assay. NO/SNO inhibits
TG activity: GSNO decreased and L-NAME increased TG
activity in HAECs. Conversely, TG2 S-nitrosylation was
increased with GSNO and decreased with L-NAME.
DTT treatment led to increased activity and decreased
S-nitrosylation, suggesting NO likely exerts its effect
through a reversible modification of protein thiols. TG2
expression levels remained constant in all these studies. In
addition, endogenous NO production was modulated using
shear stress (20 dyne/cm2, 24 hour, using cone-and-plate
viscometer) in the presence and absence of NOS inhi-
bitor L-NAME (200 mol/L), and TG2 activity and
S-nitrosylation were measured. Effect of shear was con-
firmed by inspecting cell alignment, increased NOS3
phosphorylation,19 and increased KLF-2 mRNA levels
(Online Figure III, A through C).28 Shear stress decreased
TG2 activity and increased S-nitrosylation compared to
static conditions. L-NAME reversed the effect of shear on
TG2 activity and S-nitrosylation (Figure 1B). In addition,
HAECs were treated with acetylcholine (1 mol/L, 30
minutes) to induce NO production. This resulted in de-
creased TG2 activity (Figure 1C) and increased TG2
S-nitrosylation.
Figure 1. TG2 is regulated by protein
S-nitrosylation in HAECs. A, NOS inhi-
bition (L-NAME; 200 mol/L, 2 hours)
and reducing agent (DTT; 200 mol/L, 1
hour) lead to increased activity and
decreased TG2 S-nitrosylation in HAECs,
but increased NO (GSNO; 200 mol/L, 1
hour) leads to decreased TG activity and
increased TG2 S-nitrosylation in HAECs.
TG2 expression is constant in all experi-
ments (*P0.05, **P0.01, ***P0.001,
1-way ANOVA with Tukey post test). B,
Laminar shear stress (LSS) (20 dyne/cm2
for 24 hours) decreases TG2 activity in
HAECs compared to unsheared controls;
L-NAME (200 mol/L, 24 hours)
increases TG2 activity toward unsheared
controls (n4 for each group), the
reverse is true for S-nitrosylation levels
(n3) (*P0.05, 1-way ANOVA with Bon-
ferroni post test). C, Cholinergic stimula-
tion of HAECs with acetylcholine (ACh)
(1 mol/L; 30 minutes) leads to
increased TG2 S-nitrosylation (n3) and
decreased TG activity (n4). The data
did not reach statistical significance.
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NO/SNO Regulates TG2 Subcellular Distribution
We next determined whether NO/SNO regulates TG2 location
in HAECs. Cells were treated with GSNO (200 mol/L),
GSNOL-cysteine (200 mol/L each), DTT (200 mol/L), or
L-NAME (20 or 200 mol/L) for 2 hours. We first determined
surface TG2 by labeling cell surface proteins with sulfo-
NHS-LC biotin followed by enrichment using streptavidin-
coated agarose. TG2 was determined in the biotinylated (Surface
TG2) fraction and in whole cell lysates (Total TG2) by Western
blotting (Figure 2A). Increased NO led to decreased surface
associated TG2. L-Cysteine is shown to increase S-nitrosylation
of intracellular proteins,29 and, indeed, corresponded to in-
creased intracellular TG2. DTT and L-NAME led to increased
surface associated TG2. Next, HAECs cultured on fibronectin-
coated coverslips were subjected to the same treatments. In this
case, we used immunofluorescence to label surface TG2 with
Cy3- and cytosolic TG2 with Cy5-conjugated secondary anti-
bodies (Figure 2B; see Methods for details) followed by analysis
using fluorescence microscopy (Cy3, green; Cy5, red). There is
an increase in the Cy3-labeled (surface/ECM) TG2 in DTT and
L-NAME (200 mol/L) conditions and decreased Cy3-labeled
TG2 in the GSNOL-cysteine–treated cells compared to un-
treated (baseline) cells. Cy3/Cy5 ratios were calculated as a
measure of surface/intracellular TG2. Finally, ECM fractions of
HAECs treated as indicated (Figure 2C) were isolated, and TG2
in the ECM was determined by Western blotting. Whereas
short-term GSNO (2 hours) treatment had no effect on ECM
associated TG2, inhibiting NOS led to increased ECM deposi-
tion of TG2, as did DTT. Together, these results demonstrate
that decreased NO leads to increased TG2 externalization.
TG2 Is the Predominant TG That Regulates
Vascular Stiffness
At least 3 TGs are expressed in vasculature.10,11 To
determine the role of TG2 specifically, we used a TG2/
mouse model. WT and TG2/ mice were treated with the
NOS inhibitor L-NAME using osmotic infusion pumps (40
mg/kg per day for 4 weeks) to assess the role of bioactive
NO in mediating TG activity in vivo. Controls were treated
with vehicle alone. Control WT mice showed much higher
TG activity compared to control TG/ mice (Figure 3A
and 3B). TG activity was increased in L-NAME–treated
WT mice (compared to control WT) but not in TG2/
mice (Figure 3A and 3B). TG2 expression was unaltered in
WT mice with L-NAME treatment and was undetected in
TG/ mice (Figure 3A and 3B). Finally, L-NAME
treatment led to increased central aortic stiffness, as
measured by PWV (Figure 3C). Consistent with existing
Figure 2. NO regulates TG2 subcellular
distribution in HAECs. A, HAECs were
treated with DTT (200 mol/L), NOS inhibi-
tor L-NAME (20 or 200 mol/L), GSNO
(200 mol/L), or GSNOL-cysteine
(200 mol/L each), and controls were left
untreated. Surface/ECM and cytosolic
TG2 levels were determined by enrichment
of surface proteins (as described in Meth-
ods); DTT and L-NAME led to increased
levels of cell surface TG2, whereas GSNO
and GSNOL-cysteine treatments led to
decreased surface TG2; total (whole cell
lysate) TG2 was unaltered (n8; *P0.05,
**P0.01). B, Immunofluorescence. In this
case, HAECs were grown on fibronectin-
coated coverslips and treated as indi-
cated. Extracellular TG2 was labeled by
treating live cells with TG2 antibody fol-
lowed by Cy3–conjugated secondary anti-
body followed by fixing, permeabilizing,
and labeling of intracellular TG2 by treating
samples with TG2 antibody followed by
Cy5-conjugated secondary antibody.
Samples were analyzed by fluorescence
microscopy, with green corresponding to
Cy3 and red corresponding to Cy5 fluo-
rescence. DTT and L-NAME (200 mol/L)
treatment led to increased surface TG2
(higher Cy3 signal than baseline), whereas
GSNOL-Cys led to decreased surface
TG2 (lower Cy3 signal than baseline). Cy3/
Cy5 ratios for the bar graph were
obtained as described in the Online Data
Supplement (n12; *P0.05; **P0.01).
C, HAECs were grown to confluence and
treated as indicated; ECM fraction was
recovered as described in Methods. DTT
and L-NAME led to increased deposition
of TG2 in the ECM, whereas GSNO treat-
ment did not alter ECM-associated TG2
compared to untreated cells (*P0.05,
**P0.01).
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literature,30 mean arterial pressures (Figure 3D) were
comparable in the WT and TG2/ mice at baseline.
L-NAME treatment led to increased blood pressure in both
WT and TG2/ mice but a significantly higher level in
TG2/ mice. Finally, carotid artery compliance measured
ex vivo by pressure– dimension analysis (Figure 3E) de-
creased in WT but not in TG/ mice with L-NAME
treatment. Pressure– dimension traces, normalized diame-
ter, and distensibility of carotids are shown in Online
Figure IV (A through C).
TG Crosslinking Activity Is Higher in Old Rat
Aorta Because of Impaired TG2 S-Nitrosylation by
Endothelium-Dependent Bioactive NO
We next addressed age-related alterations in TG activity in
aorta of rats. Old rats have higher TG crosslinking activity,
as measured using the biotin(amido)pentylamine incorpo-
ration assay (Figure 4A) and immunohistochemistry (Fig-
ure 4B). TG2 abundance remained unchanged (Figure 4A
and 4B). We probed the role of endothelium-dependent
bioactive NO in regulating TG2 by inhibiting NOS using
L-NAME (200 mol/L, 2 hour; Figure 4A) and by com-
paring endothelium-denuded (E) with intact (E) aortic
rings (Figure 4C). Both NOS inhibition and removal of
endothelium (diminished NO availability) led to a marked
increase in TG activity, lending support to the role of NOS
in modulating TG activity. We also measured greater
levels of S-nitrosylated TG2 in young compared to old rat
aorta, suggesting a role for S-nitrosylation in modulating
TG activity (Figure 4D). We next tested whether in vivo
chronic TG inhibition using cystamine (40 mg/kg per day
for 4 weeks) could improve vascular stiffness (as measured
Figure 3. TG2 is the TG important in
mediating vascular stiffness. NOS was
inhibited in WT and TG2/ mice using
L-NAME (20 mg/kg per day) adminis-
tered through osmotic infusion pumps
for 4 weeks. A and B, TG activity
increases with L-NAME inhibition of NOS
in WT mice but not in TG/ mice,
whereas TG2 expression is unchanged.
C, PWV increases in L-NAME–treated
WT but not TG2/ mice compared to
untreated controls. D, Mean arterial
pressure (MAP) for mice were measured
before and after treatment. E, Compli-
ance of carotid artery measured ex vivo
by pressure–dimension analysis
decreases in L-NAME–treated WT but
not TG2/ mice compared to untreated
controls (n8 each group; *P0.05,
**P0.01; 1-way ANOVA followed by
Bonferroni post test).
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by PWV) associated with aging. Cystamine-treated ani-
mals show significantly lower PWV at the end of the
treatment period compared to controls (Figure 4E). Blood
pressure decreased with age equally in both cystamine-
treated and untreated rats (Figure 4F).
TG Activity Is Increased in Aging Humans
We compared the TG activity and expression in young and
old human aorta obtained at autopsy. TG activity (Figure
5A) and crosslinks (Figure 5B) were higher in aged
humans compared to young controls. This suggests that
age-related increases in TG2 activity contribute to vascular
changes in humans and that TG2 is a potential target for
therapy in treating age-related vascular dysfunction.
Discussion
Aging is accompanied by increased remodeling of the
vascular wall and altered endothelial function. Whereas
Figure 4. TG2 activity augmented and S-nitrosylation is diminished in aging rat aorta in an NOS3-dependent manner. A, TG
activity is higher in old rats compared to young (n6 each group; *P0.05 by Student’s t test); ex vivo L-NAME treatment markedly
enhances activity in young but not in old. B, TG-specific crosslinks determined by immunohistochemistry are higher in old compared to
young rat aorta; expression is unchanged (right). C, TG activity is markedly enhanced in aortic segments of young rats lacking endo-
thelium (E) compared to intact endothelium (E), suggesting endothelial NO is important in regulating TG2 from other cellular sources
(n6). D, S-Nitrosylation of TG2 diminishes with age, whereas expression is unchanged. E, Untreated rats show an increase in PWV
over 12 weeks, whereas rats treated with TG inhibitor cystamine (40 mg/kg per day) administered via osmotic infusion pumps for 12
weeks show significantly lower PWV compared to untreated animals (n8 each group). F, Mean arterial pressure (MAP) decreases with
age in rats and is not significantly different in age-matched treated and untreated groups (n8 each group; *P0.05, **P0.01,
***P0.001; 1-way ANOVA with Tukey post test).
Figure 5. TG activity increases with age in
human aorta. Samples were obtained during
autopsy, and TG2 activity/expression was deter-
mined. A, TG activity is higher in old (ages 62 to
101 years) compared to young (ages 33 to 49
years) human aorta; expression levels are unal-
tered with age. B, TG-specific crosslinks increase
with age (immunohistochemistry) (n8; *P0.05,
**P0.01 by Student’s t test).
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elastin fracture, increased collagen content, and increased
activity of MMP-2 are known to be important mediators of
this phenomenon, the role of TG2 in vascular remodeling
and atherosclerosis is emerging.4,30 Previous studies have
shown that TG2 is expressed in all layers of the blood
vessel.4,5 The N-(-glutamyl)lysine crosslinks formed by
TG are mainly found in the adventitia and the (sub)endo-
thelium. TG2 is thought to be inhibited by S-nitrosylation14
and is involved in small-artery remodeling in an NO-
dependent manner.7 In this study, we demonstrate that TG
activity increases with age in rat and human aorta whereas
TG2 S-nitrosylation decreases. It is well accepted that
aging is associated with diminished NO bioavailability.
Together, these observations suggest that an NO-
dependent posttranslational modification of TG2 likely
mediates the increase in activity observed in aging. It is
interesting to note that the abundance of TG2 re-
mained unchanged in both aging human and rat aorta, an
observation supported by a recent proteomic study identi-
fying age-associated alterations in protein expression lev-
els in rat aorta.31 This highlights the importance of
nitrosoredox-dependent posttranslational modifications in
determining function and their role in human disease32 and
stresses the critical role of functional proteomics in target
identification.
TG2/ mice do not show any overt cardiovascular
phenotype when unchallenged, but have altered re-
sponse(s) compared to WT littermates under several str-
esses.33 Examples include delayed inward remodeling of
resistance arteries in response to surgical reduction of
blood flow34 and L-NAME–induced hypertension.30 The
presence of remodeling in TG2/ mice is attributable to
alternative mechanisms involving other members of the
TG superfamily (eg, factor XIII and TG5). Additionally, in
the case of L-NAME induced hypertension, TG2/ mice
show enhanced blood pressure responses but smaller
structural changes compared to WT littermates.30 In this
study, we used L-NAME inhibition of NOS in WT and
TG2/ mice and show that TG2 is the predominant
TG-mediating conduit artery (aortic) stiffness. WT mice
show a significant increase in arterial stiffness (PWV) in
response to NOS inhibition by L-NAME, whereas TG2/
mice do not. The distensibility of carotid arteries from
TG2/ is significantly higher than WT at baseline (On-
line Figure IV, B); however, their compliance is compa-
rable. Additionally, whereas TG2 expression was undetec-
ted in TG2/ mice, the aorta of these mice stained
positively for the -(-glutamyl)lysine crosslinks, albeit at
lower intensities than WT mice. We predict that the lower
matrix crosslinking leads to increased distensibility, but
there are other complementary/compensating mechanisms
contributing toward maintaining compliance in the
TG2/ mice, such as those observed in small arter-
ies.10,30,34 This remains to be confirmed.
In HAECs, NOS-dependent NO regulates TG2
S-nitrosylation and activity, as demonstrated using NOS
inhibitor L-NAME, shear stress, and acetylcholine. Fur-
thermore, we show that decreased nitrosylation is accom-
panied by increased externalization of TG2. The specific
enzymatic reaction catalyzed by TG2 is dependent on its
subcellular location. In the cytosol, with high GTP and low
Ca2 levels, the crosslinking activity of TG2 is held latent.
Conversely, because extracellular TG2 encounters low
GTP and high Ca2 levels, it performs its transamidation
reaction. Our study suggests that sustained decrease in NO
bioavailability, such as those encountered in aging vascu-
lature, can lead to decreased TG2 S-nitrosylation, in-
creased externalization, and, thus, increased matrix
crosslinking. Furthermore, our data suggest that endothe-
lial NO regulates the activity of TG2 derived from other
cell types (fibroblasts and SMCs) in the aorta, as denuding
the endothelium (and thereby reducing bioavailable NO)
leads to increased TG2 activity. Thus, the role of endothe-
lium derived bioavailable NO in regulating S-nitrosylation
of TG2 derived from other cell types of the vessel remains
to be elucidated, for example, through coculture systems.
In addition to reduced NO bioavailability, Ca2 dysregu-
lation in aging aorta may also contribute to TG2 activity
because Ca2 is essential for TG2 crosslinking activity and
can also influence TG2 S-nitrosylation.14 Moreover, dys-
regulated denitrosylation pathways can also contribute to
this phenomenon. The contribution(s) of these mechanisms
to TG2 regulation in aging remains to be studied.
It is important to note that protein crosslinks catalyzed
by TG2 are very stable and have a very low turnover. Thus,
increased crosslinks observed in the aorta of aged rats and
humans could be either attributable to increased TG2
activity or a result of accumulation of crosslinks at
constant TG2 levels. In both cases, TG2 crosslinking
activity contributes to the resultant vascular stiffening. Our
study demonstrates that loss of NO bioavailability leads to
increased TG2 transamidation activity and might acceler-
ate the stiffening process. Thus, TG2 inhibition is a
potential therapeutic route toward treating age-related
vascular disease.
Finally, in addition to increased matrix crosslinking,
there are a number of downstream mechanisms that might
ultimately contribute to TG2-mediated increases in vascu-
lar stiffness. These include integrin signaling,35 activating
RhoA,36 and enhanced growth factor receptor signaling,37
which can contribute to vascular proliferation and fibrosis.
In addition, TG2 is important for targeting of latent
transforming growth factor  complex, which leads to
enhanced synthesis and deposition of matrix proteins
including collagen38 in an NO-dependent manner.16 For
example, a recent study demonstrated significantly lower
plaque areas in TG2-ApoE double knockout mice on a
Western-type diet compared to ApoE-null mice. The
plaques in the double knockout also had lower collagen
content and increased inflammation and, therefore, more
unstable plaque. This was matched by decreased trans-
forming growth factor  activity. Here again, factor XIII
was shown to play a potential compensatory role in the
double knockout mice.39
In conclusion, we show that TG2 is the primary TG
mediating age-associated stiffening of conduit arteries.
TG2 is regulated by endothelium-derived bioavailable NO;
TG2 S-nitrosylation decreases and crosslinking activity
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increases with age and contributes to a decrease in vascular
compliance. The cellular source of TG2 in the vasculature
that contributes to this phenomenon remains to be
identified.
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Novelty and Significance
What Is Known?
● Diminished NO bioavailability in aging conduit arteries contributes to
increased vascular stiffness.
● Tissue transglutaminase (TG2) is involved in small artery remodeling
in response to various pathophysiologic stresses.
● TG2 activity is thought to be regulated by NO via S-nitrosylation.
What New Information Does This Article Contribute?
● TG2 crosslinking activity and externalization are regulated by NO in
endothelial cells.
● Endothelium-derived NO constrains TG2 activity in rat aorta through
S-nitrosylation.
● Decreased TG2 S-nitrosylation leads to increased crosslinking activity
in old rat aorta.
● TG inhibition ameliorates age-associated increase in vascular stiff-
ness in rats.
Age-associated increase in central vascular stiffness and result-
ant systolic hypertension are the hallmark of the aging vascular
system and contribute to cardiovascular morbidity in the elderly.
Therapy, however, remains elusive because there are few
established protein targets. In this study, we established the role
of TG2 in mediating vascular stiffness. We show that TG2
activity increases with age in the aorta of rats and humans. We
demonstrate that decreased NO leads to decreased TG2
S-nitrosylation and increased TG2 externalization and crosslink-
ing activity in endothelial cells. We further demonstrate that
endothelium-derived NO regulates TG2 crosslinking activity and
TG2 S-nitrosylation diminishes with age in rat aorta. Finally, TG
inhibition in rats prevents age-associated increases in vascular
stiffness. This is the first study demonstrating the role of
decreased S-nitrosylation of TG2 by endothelium-derived NO in
increased vascular stiffness with aging. This study provides a
foundation to further study the therapeutic potential of TG2 in
treated age-related vascular disease.
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Correction
Decreased S-Nitrosylation of Tissue Transglutaminase Contributes to Age-Related Increases in
Vascular Stiffness
In the article that appears on page 117 of the July 9, 2010, issue, all L-NAME treatments in cells
and tissue were performed for 24 hours and not 2 hours as originally reported in the manuscript.
Each instance of an incorrect treatment time has been corrected throughout.
The authors regret this error. This error has been noted and corrected in the online version of
the article, which is available at http://circres.ahajournals.org/cgi/content/full/107/1/117
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Supplemental Material: 
Detailed Methods:  
Animals: The animal protocols used in this paper have been approved by the Institutional 
Animal Care and Use Committee at Johns Hopkins University School of Medicine.  
Fisher 344 rats were utilized for this study and were supplied by the National Institute of 
Aging. Young animals were approximately 3 months of age while old animals were 
between 22-24 months of age. Male TG2-/- mice (a kind gift from Robert Graham, Victor 
Chang Cardiovascular Institute NSW Australia) were used (3 – 5 months of age) in the 
study with BL6129S as background. All animals were fed ad libitum and had free access 
to drinking water.  
Cell cultures: Human Aortic Endothelial Cells (HAEC) were purchased from Cascade 
Biologics, cultured using ECM Media (ScienCell labs) and used between passage 7 and 
10. Intact cells were treated as indicated and used to determine TG2 activity, expression, 
and S-nitrosylation. NIH3T3 cells stably transfected with full length TG2 construct were 
cultured and used as described in literature1, 2.  
Shear stress: HAEC were grown to ~80% confluence and subjected to a laminar shear 
stress of 20 dynes/ cm2 for 20 h using a cone-and-plate viscometer3-5. BPA and Ca2+ were 
added (see below for activity assay) and plates sheared for an additional 4 h. Alternately, 
cells were sheared at 20 dynes/cm2 for 24 h, and used for S-nitrosylation assays. 
TG2 expression: Expression was determined by western blotting using CUB7402 
antibody (Neomarkers) for HAEC and rat tissue (1:5000 dilution in 3 % milk), and rabbit 
polyclonal antibody (Ab-4, Neomarkers, 1:1000) for mouse aortic tissue. Blots were 
analyzed by densitometry using the ImageJ software.  
Transglutaminase Activity Assay: A dot blot assay was used to determine 
Transglutaminase activity as described6 with minor modifications; we used 
HRP-conjugated streptavidin and chemiluminescent detection instead of infrared 
fluorophore. The assay is based on the incorporation of the TG substrate 
5-(biotinamido)pentylamine (BPA) (Pierce, USA) into proteins7, 8. In brief, intact 
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cells/tissues were incubated with 1 mM BPA and 2.5 mM Ca
2+
 at 37 °C for 4 h in culture 
media and then rinsed free of unreacted BPA using PBS. Following this, samples were 
homogenized/lysed to recover proteins. 1 – 2 ug total proteins were loaded onto 
nitrocellulose membrane (BioRad Dot Blot apparatus). The membrane was rinsed and 
blocked in 3 % BSA overnight and probed with HRP-conjugated streptavidin (Amersham 
Bioscience; 1:10,000 dilution in 1% BSA) to determine BPA incorporation. Blots were 
then stripped using Restore Plus stripping buffer (Pierce) and reprobed with GAPDH to 
determine protein loading. BPA incorporation and GAPDH levels were determined by 
densitometry analysis using the NIH Image J software. For each sample, activity was 
calculated as a ratio of BPA/GAPDH. In one blot, we had 2 or more biological replicates of 
each group; therefore, the average value of the BPA/GAPDH ratio from the baseline 
group was set to 100% activity. A time course of BPA incorporation in HAEC is shown in 
Fig S1A and a comparison to the standard western blotting approach is provided (Fig 
S1B).  
S-nitrosylation assay: TG2 S-nitrosylation was determined using the biotin switch9, 10 
assay in cell lysates/tissue homogenates. As the activity assay also relies on 
biotinylation, the S-nitrosylation assays were performed on a separate set of samples in 
parallel wtih the activity assays. 100 µg samples were blocked using methylmethane 
thiosulfonate (MMTS, 50 mM in Tris-HCl pH 7.5 (50 mM), neocuproine (0.01mM), SDS (1 
% w/v), pH 7.5)) at 50 °C accompanied by vigorous shaking. Proteins were recovered by 
cold acetone precipitation, resuspended in labeling buffer (Tris HCl (50 mM) pH 7.5, 
EDTA (1 mM)) and labeled with HPDP Biotin (4 mM final concentration) for 1 h at room 
temperature in the presence or absence of the reducing agent ascorbate (5 mM). After 
the labeling step, proteins were recovered by acetone precipitation, and biotinylated 
proteins enriched using streptavidin coated agarose. Samples were resolved by SDS 
PAGE and probed with TG2 antibody to determine TG2 S-nitrosylation levels. 
Densitometry analysis was performed using ImageJ software.  
Isolation of Cell surface proteins: Surface proteins were enriched using sulfo-NHS-LC 
biotin (Pierce). Briefly, HAECs were cultured to confluence in 100 mm dishes and treated 
with indicated drugs/reagents, Plates were then rinsed in cold PBS and surface proteins 
were biotinylated using sulfo-NHS-LC-biotin (Pierce) following manufacturer’s protocol. 
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At the end of labeling, cells were trypsinized, recovered in PBS, and counted. 1.5 x 106 
cells from each sample were pelleted and lysed in 200 µl 1x RIPA buffer. Biotinylated 
proteins were enriched using streptavidin-coated agarose. TG2 was determined by 
western blotting.  
Recovery of ECM proteins: HAEC were grown to confluence and treated with indicated 
reagents. ECM was recovered following the protocol described by Soucy et al11. In brief, 
cells were rinsed twice in PBS, Cellular and nuclear materials were extracted by 
incubation with cell removal solution (0.05% Triton X-100 (Fisher Scientific, Pittsburgh, 
PA) and 50 mM NH4OH (Sigma, St. Louis, MO) in PBS) until the cells were floating. The 
matrix was then briefly washed once with 50 mM NH4OH (in PBS) and then three times 
with phosphate buffered saline (PBS) (Quality Biological Inc, Gaithersburg, MD). ECM 
was scraped into 1x RIPA buffer and TG2 was determined by western blotting.  
Immunofluorescent staining of TG2: HAECs were grown on fibronectin coated 
coverslips and treated as indicated. The entire labeling procedure was performed in the 
dark. Extracellular/ ECM associated TG2 was stained first in live cells as follows: samples 
were rinsed in cold PBS, blocked (PBS with 0.1 % BSA) for 15 min, and treated with TG2 
antibody (CUB7402, 1:100) at 4 °C for 45 min. Samples were then rinsed 3 times in cold 
PBS, and treated with Cy3-conjugated goat-anti-mouse IgG (1:100, Jackson Immuno) at 
4 °C for 45 min. Then, intracellular TG2 was labeled: samples were rinsed in cold PBS, 
fixed (3 % paraformaldehyde 45 min) and permeabilized (PBS containing 0.1% BSA and 
2% w/v saponin; 15 min). Next, samples were blocked using Goat Serum Dilution Buffer 
(GSDB; 10 % Goat serum v/v/, 2 % saponin w/v, 10 mM Glycine; 30 min), treated with 
primary antibody again (1:100 in GSDB; 45 min), followed by rinsing and labeling with 
Cy5-conjugated goat-anti-mouse IgG (Jackson Immuno, 1:100 in GSDB; 45 min). 
Samples were then mounted using FluorSave reagent containing DAPI (Calbiochem). 
Samples were sealed with clear nail polish and imaged on a Nikon Eclipse 80i equipped 
with a photometrics CoolSnap HQ2 camera. Images were acquired at 10x magnification 
with the exposure time kept constant for each channel across all samples. The object 
count function was used to determine live cells by counting nuclei. Cy3 and Cy5 
intensities were determined and (Cy3/Cy5) ratios were calculated and divided by number 
of cells in the field to yield extracellular/intracellular TG2 per cell. In addition, 
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representative images were captured at 40x magnification, again, keeping exposure 
times constant for all samples.   
In vivo NOS inhibition in mice: WT (BL6129S) and TG2-/- mice were treated with the 
NOS inhibitor L-NAME for a period of 4 weeks. Animals were randomized into two groups 
and implanted with an osmotic pump (Alzet) filled with a four week dose of either L-NAME 
(20 mg/kg/day) or vehicle control. Pulse wave velocity was measured as described below. 
At the end of the study, the aortas were excised and TG2 activity and expression were 
determined.  
In vivo inhibition of transglutaminase in aging rats: 18-19 month old rats were treated 
with the TG inhibitor cystamine for a period of 12 weeks to assess the role of TG in 
mediating vascular stiffness. Animals were randomized into two groups and implanted 
with an osmotic pump (Durect Corporation) filled with a 4 week dose of either cystamine 
(40 mg/kg/day) or vehicle control. Pumps were exchanged every 4 weeks for 3 months. 
Pulse wave velocity was measured as described below. At the end of the study, rats were 
euthanized, and aorta excised for biochemical assays.   
Pulse wave velocity (PWV) measurements: To assess vascular stiffness, the aortic 
PWV was measured at the beginning and end of the study period using high frequency 
Doppler with a Doppler Signal Processing Workstation (Indus Instruments) as described 
previously12, 13. In mice, blood pressure was measured concurrently using an XBP1000 
non-invasive tail blood pressure system (Kent Scientific Corporation) at the beginning 
and end of treatment period. For rats, BP was measured noninvasively at the beginning of 
the treatment period. At the end of the treatment period, intraventricular pressure was 
measured in anesthetized rats using a combined conductance micromanometric catheter 
as previously described14.  
Carotid artery compliance:  To investigate passive vascular properties, the carotid 
artery was dissected and cannulated in a perfusion chamber.  The artery was perfused 
with oxygenated calcium-free Krebs buffer using a peristaltic pump (Cole-Parmer 
Instrument Co.), which also continuously monitored perfusion pressure.  Pressure was 
incrementally increased from 0 to 120 mmHg in steps of 10 mmHg, each for 30 second 
intervals.  Vessel outer diameter was simultaneously recorded using microscopic 
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imaging and video dimension analysis (Analog Digital Instruments). Compliance can be 
described as the ability to stretch and hold volume (V). Since the aortic section is 
cannulated at fixed length, the relative compliance can be calculated from the relationship 
between luminal pressure (P) and cross-sectional area (A), or diameter (d), assuming a 
circular lumen.    
ܥ݋݉݌݈݅ܽ݊ܿ݁ ൌ  ∆ܸ∆ܲ  ൎ  
∆ܣ
∆ܲ  ൎ  
∆݀ଶ
∆݌  
To minimize the influence of aortic geometry, the vascular distensibility can be calculated 
by normalizing the stressed condition (V, A, or d2) to the unstressed condition (Vo, Ao, or 
d02)15  
ܦ݅ݏݐ݁݊ݏܾ݈݅݅݅ݐݕ ൌ  ∆ܸ
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Human tissue: Thoracic descending aortic segments were taken from 16 subjects (8 
young (33-49 yr old) and 8 old (62-101 yr old) undergoing autopsy as part of a wider study 
of vascular tissues as described16. These tissues were processed to be ~ 1 x 3 cm, frozen 
and kept at -80 °C until use. Ten iliac arteries from 5 young (33-49 yr old) and 5 old 
(62-101 yr old) individuals were also used from the same collection. Unstained slides, for 
immunohistochemistry (IHC), were created from the formalin fixed paraffin-embedded 
iliac artery tissues. The collection of all tissues was approved by the institutional review 
board (IRB) of The Johns Hopkins Hospital. The previously detailed assays (TG2 activity, 
Western Blot expression) were also carried out using human tissue collected post 
mortem.   
Immunohistochemistry in aortic samples  
TG2 expression/ cross links: All IHC staining was performed using a mouse antihuman 
TG2 antibody for expression (1:100, Covalab; France) or monoclonal antibody 81D4 
(1:100 dilution, Covalab, France) for cross-links. Staining was performed using the Lab 
Vision UltraVision Detection System, per the manufacturer’s instructions (Lab Vision, 
Fremont, CA). Briefly, following deparaffinization and rehydration, slides were incubated 
with 3% H2O2 to block endogenous peroxidase activity. Antigen retrieval was done using 
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0.01M sodium citrate buffer in a microwave oven for 10 minutes. Slides were then blocked 
with Ultra V Block and incubated with the mouse anti-human TG2 antibody (1:100 
dilution) at room temperature for 90 minutes. Slides were incubated with biotinylated 
anti-mouse secondary antibody for 10 minutes at room temperature, and subsequently 
incubated with streptavidin peroxidase. Slides were then incubated with DAB chromagen 
and counterstained with hematoxylin before being coverslipped.  
Scoring of IHC staining intensity  
IHC staining intensity was evaluated in the tunica media and was scored based on the 
strongest staining of the vessel using a 0-3 (0 = none, 1 = mild, 2 = moderate, 3 = strong) 
scale. Scoring was performed independently and blindly by three authors (ET, AMM and 
MKH) and the average score for each tissue was used.  
Data analysis: All western blots and dot blots were analyzed by densitometry using the 
ImageJ software (NIH). Results are expressed as a percentage change relative to the 
average value measured in the baseline group. For statistics, 1-way ANOVA and Tukey 
post test were used to compare three or more groups; unpaired t-test was used to 
compare two groups using GraphPad Prism software. All data are represented as 
Mean±SEM.     
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Online Figure I: A dot blot approach was developed to measure TGase activity. HAEC 
were incubated with BPA for indicated time. Proteins were recovered and BPA incorporation, 
TG2 expression, and GAPDH (loading control) were measured. A) 1 μg protein from each 
sample was loaded onto nitrocellulose membrane using the BioDot dot blot apparatus (Bio 
Rad), blocked overnight in 3% BSA, followed by detection of biotin incorporation using 
streptavidin-conjugated HRP (1:10,000 in 1% BSA; Amersham Bioscience); B) Biotin 
incorporation was determined by western blotting using 10 μg protein from each sample; TG2 
expression blot is also shown; C) densitometry analysis of Dot blot and western blot 
approaches shows excellent correlation. The dot blot approach is a good representation of 
TG activity. It is sensitive and faster and requires less protein (1 – 2 μg) than the western blot 
approach typically used; and D) densitometry analysis of TG2 expression All densitometry         .   
analyses were performed using ImageJ software (NIH). Data are representative of 4 
independent experiments.
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Online Figure II: NO regulates TG2 activity. NIH3T3 cells stably transfected with 
mifepristone-inducible plasmid encoding full-length TG2 were stimulated for 8 h and used. 
GSNO (200 μM, 1 h) increased TG2 S-nitrosylation while expression was not altered (top); 
TG2 activity decreased with GSNO treatment (bottom).
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Online Figure III: Effect of shear on HAEC. HAEC were grown to 80 % confluence and 
subjected to 20 dynes/cm2 shear stress (= 400 rpm). A) Cell alignment in the direction of 
shear was confirmed by brightfield microscopy; B) KLF-2 mRNA was determined by RT-
PCR, and C) phospho-eNOS levels were determined by western blotting. 
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Online Figure IV: Ex vivo pressure 
dimension relationship of carotid artery. 
A) pressure-diameter correlation in WT and 
TG2-/- mice with and without L-NAME 
treatment; B) Pressure vs. Normalized 
diameter; and C) Distensibility (= slope of 
normalized graph B).
215228/R1     10
  
 
Supplemental References: 
1. Hang J, Zemskov EA, Lorand L, Belkin AM. Identification of a novel recognition 
sequence for fibronectin within the NH2-terminal beta-sandwich domain of tissue 
transglutaminase. J Biol Chem. 2005;280:23675-23683. 
2. Zemskov EA, Mikhailenko I, Strickland DK, Belkin AM. Cell-surface 
transglutaminase undergoes internalization and lysosomal degradation: an 
essential role for LRP1. J Cell Sci. 2007;120:3188-3199. 
3. Boo YC, Sorescu G, Boyd N, Shiojima I, Walsh K, Du J, Jo H. Shear stress 
stimulates phosphorylation of endothelial nitric-oxide synthase at Ser1179 by 
Akt-independent mechanisms: role of protein kinase A. J Biol Chem. 
2002;277:3388-3396. 
4. Hwang J, Saha A, Boo YC, Sorescu GP, McNally JS, Holland SM, Dikalov S, 
Giddens DP, Griendling KK, Harrison DG, Jo H. Oscillatory shear stress stimulates 
endothelial production of O2- from p47phox-dependent NAD(P)H oxidases, 
leading to monocyte adhesion. J Biol Chem. 2003;278:47291-47298. 
5. Shin J, Jo H, Park H. Caveolin-1 is transiently dephosphorylated by shear 
stress-activated protein tyrosine phosphatase mu. Biochem Biophys Res 
Commun. 2006;339:737-741. 
6. McConoughey SJ, Niatsetskaya ZV, Pasternack R, Hils M, Ratan RR, Cooper AJ. 
A nonradioactive dot blot assay for transglutaminase activity. Anal Biochem. 
2009;390:91-93. 
7. Hiiragi T, Sasaki H, Nagafuchi A, Sabe H, Shen SC, Matsuki M, Yamanishi K, 
Tsukita S. Transglutaminase type 1 and its cross-linking activity are concentrated 
at adherens junctions in simple epithelial cells. J Biol Chem. 
1999;274:34148-34154. 
8. Lee KN, Maxwell MD, Patterson MK, Jr., Birckbichler PJ, Conway E. Identification 
of transglutaminase substrates in HT29 colon cancer cells: use of 
5-(biotinamido)pentylamine as a transglutaminase-specific probe. Biochim 
Biophys Acta. 1992;1136:12-16. 
9. Jaffrey SR, Erdjument-Bromage H, Ferris CD, Tempst P, Snyder SH. Protein 
S-nitrosylation: a physiological signal for neuronal nitric oxide. Nat Cell Biol. 
2001;3:193-197. 
10. Jaffrey SR, Snyder SH. The biotin switch method for the detection of S-nitrosylated 
proteins. Sci STKE. 2001;2001:PL1. 
11. Soucy PA, Romer LH. Endothelial cell adhesion, signaling, and morphogenesis in 
fibroblast-derived matrix. Matrix Biol. 2009;28:273-283. 
12. Soucy KG, Ryoo S, Benjo A, Lim HK, Gupta G, Sohi JS, Elser J, Aon MA, Nyhan 
D, Shoukas AA, Berkowitz DE. Impaired shear stress-induced nitric oxide 
production through decreased NOS phosphorylation contributes to age-related 
vascular stiffness. J Appl Physiol. 2006;101:1751-1759. 
13. Tuday EC, Meck JV, Nyhan D, Shoukas AA, Berkowitz DE. Microgravity-induced 
changes in aortic stiffness and their role in orthostatic intolerance. J Appl Physiol. 
2007;102:853-858. 
14. Thompson-Torgerson CS, Champion HC, Santhanam L, Harris ZL, Shoukas AA. 
Cyclohexanone contamination from extracorporeal circuits impairs cardiovascular 
function. Am J Physiol Heart Circ Physiol. 2009;296:H1926-1932. 
15. Soucy KG, Lim HK, Attarzadeh DO, Santhanam L, Kim JH, Bhunia AK, Sevinc B, 
215228/R1     11
  
 
Ryoo S, Vazquez ME, Nyhan D, Shoukas AA, Berkowitz DE. Dietary Inhibition of 
Xanthine Oxidase Attenuates Radiation-Induced Endothelial Dysfunction in Rat 
Aorta. J Appl Physiol. 2010. 
16. Halushka MK, Cornish TC, Lu J, Selvin S, Selvin E. Creation, validation, and 
quantitative analysis of protein expression in vascular tissue microarrays. 
Cardiovasc Pathol. 2009. 
 
 
215228/R1     12
